Update on the termination of the grant agreement with the NCBiR concerning project CT-02

Current report: 24/2023

Date of preparation: 20 June 2023

Subject: Update on the termination of the grant agreement with the NCBiR concerning project CT-02

Legal basis: Article 17(1) MAR - inside information

With reference to current report 21/2023 dated 6 June 2023 ("Current Report"), the Management Board of Captor Therapeutics S.A., with its registered office in Wrocław ("Company"), announces that the Company has submitted a letter ("Letter") to the National Centre for Research and Development ("NCBiR") in which the Company indicates that it is considering an attempt to repeal in full the effects of the statement on the termination of agreement POIR.01.01.01-00-0741/19 dated 1 June 2020 made by the NCBiR ("Agreement") as well as challenging the legal grounds for demanding the return of the entire grant received.

In the Letter, the Company pointed out, in particular, the factual assessment of the project's course different from NCBiR's and the lack of justification for the application of grounds for termination of the Agreement indicated by NCBiR, as well as emphasized that the demand for the return of the entire grant received is excessive and unjustified. The Company declared its willingness to immediately enter into talks with NCBiR in order to resolve this dispute amicably.

In connection with the submission of the Letter, the Company informs that, to date, it has not repaid the funds to which the Company was called by NCBiR in its statement of termination of the Agreement.

Other projects undertaken by the Company and funded by NCBiR are subject to ongoing evaluation by NCBiR and the Company is not aware of any objections to questioning the progress of the other projects. 

The Company will report on further issues relating to the CT-02 project and the subject of this report as required by law.